Weight Loss and Abdominal Fat Responses to Different Diet Compositions

NCT ID: NCT01034046

Last Updated: 2010-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the effectiveness of two different reduced calorie diets that have different combinations of carbohydrate, fat, and protein content in 2 groups of study participants: insulin sensitive participants and insulin resistant participants. The hypothesis of the study is that people with high and low levels of insulin resistance may respond differently to different diet compositions in a real-world environment using meals that are commonly available.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Insulin Resistance Metabolic Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Insulin Sensitive Study Participants

Insulin sensitive subjects stratified using fasting insulin levels.

Group Type ACTIVE_COMPARATOR

Low Carbohydrate Diet

Intervention Type OTHER

Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.

Low Fat Diet

Intervention Type OTHER

Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.

Insulin Resistant Study Subjects

Insulin resistant subjects stratified using fasting insulin levels.

Group Type ACTIVE_COMPARATOR

Low Carbohydrate Diet

Intervention Type OTHER

Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.

Low Fat Diet

Intervention Type OTHER

Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low Carbohydrate Diet

Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.

Intervention Type OTHER

Low Fat Diet

Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females between 18 and 65 years of age.
* BMI 30-40 kg/m2
* Stable weight within 10 lb (+/-) for last 2 months

Exclusion Criteria

* Pregnant or lactating.
* Must not currently be part of a structured weight loss program
* Taking a medication for diabetes (such as insulin, metformin, glyburide, glipizide, Byetta, pioglitazone, or rosiglitazone) or a medication such as systemic glucocorticoids that are known to affect blood sugar or blood insulin.
* Beck Depression Inventory (BDI Score \>19 and/or positively endorses the suicide question on the BDI-II)
* Taking any chronic medication that has not had a stable dose for 1 month or longer.
* Diabetes mellitus defined as a fasting glucose ≥ 126 mg/dL on screening.
* Taking medications or dietary supplements that cause weight gain or weight loss (eg. antipsychotics (Seroquel, Zyprexa, and Risperdal) and/or anorectics).
* Clinically significant laboratory abnormalities at the opinion of the investigators.
* History of Bariatric Surgery
* A history of:

* Type 2 diabetes, type 1 diabetes, or diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g. Cushing's syndrome and acromegaly.
* Liver disease, such as cirrhosis, or chronic active hepatitis B or C.
* Use of investigational drugs within 30 days of visit 1
* A pacemaker.
* Hospitalization for depression in the past 6 months, history of moderate to severe major depression.
* Any other condition that in the investigators' or sponsor's opinion could interfere with the results of the trial.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jenny Craig, Inc.

INDUSTRY

Sponsor Role collaborator

University of Nevada, Las Vegas

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University of Nevada School of Medicine, Reno

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Raymond A Plodkowski, MD

Role: PRINCIPAL_INVESTIGATOR

University of Nevada School of Medicine, Reno

Sachiko T St. Jeor, PhD, RD

Role: PRINCIPAL_INVESTIGATOR

University of Nevada School of Medicine, Reno

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Center for Nutrition and Metabolism at the University of Nevada School of Medicine, Reno

Reno, Nevada, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B08/09-031

Identifier Type: -

Identifier Source: org_study_id